Literature DB >> 22194329

Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations.

Yechun Xu1, Min-jun Li, Harry Greenblatt, Wuyan Chen, Aviv Paz, Orly Dym, Yoav Peleg, Tiantian Chen, Xu Shen, Jianhua He, Hualiang Jiang, Israel Silman, Joel L Sussman.   

Abstract

β-Secretase (β-site amyloid precursor protein-cleaving enzyme 1; BACE1) is a transmembrane aspartic protease that cleaves the β-amyloid precursor protein en route to generation of the amyloid β-peptide (Aβ) that is believed to be responsible for the Alzheimer's disease amyloid cascade. It is thus a prime target for the development of inhibitors which may serve as drugs in the treatment and/or prevention of Alzheimer's disease. In the following determination of the crystal structures of both apo and complexed BACE1, structural analysis of all crystal structures of BACE1 deposited in the PDB and molecular dynamics (MD) simulations of monomeric and `dimeric' BACE1 were used to study conformational changes in the active-site region of the enzyme. It was observed that a flap able to cover the active site is the most flexible region, adopting multiple conformational states in the various crystal structures. Both the presence or absence of an inhibitor within the active site and the crystal packing are shown to influence the flap's conformation. An open conformation of the flap is mostly observed in the apo structures, while direct hydrogen-bonding interaction between main-chain atoms of the flap and the inhibitor is a prerequisite for the flap to adopt a closed conformation in the crystal structures of complexes. Thus, a systematic study of the conformational flexibility of the enzyme may not only contribute to structure-based drug design of BACE1 inhibitors and of other targets with flexible conformations, but may also help to better understand the mechanistic events associated with the binding of substrates and inhibitors to the enzyme.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22194329     DOI: 10.1107/S0907444911047251

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  20 in total

1.  Microsecond molecular dynamics simulation of Aβ42 and identification of a novel dual inhibitor of Aβ42 aggregation and BACE1 activity.

Authors:  Yuan-yuan Wang; Li Li; Tian-tian Chen; Wu-yan Chen; Ye-chun Xu
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

2.  In silico study of peptide inhibitors against BACE 1.

Authors:  Navya Raj; Agnes Helen; N Manoj; G Harish; Vipin Thomas; Shailja Singh; Seema Sehrawat; Shaguna Seth; Achuthsankar S Nair; Abhinav Grover; Pawan K Dhar
Journal:  Syst Synth Biol       Date:  2015-03-19

3.  D3R Grand Challenge 4: prospective pose prediction of BACE1 ligands with AutoDock-GPU.

Authors:  Diogo Santos-Martins; Jerome Eberhardt; Giulia Bianco; Leonardo Solis-Vasquez; Francesca Alessandra Ambrosio; Andreas Koch; Stefano Forli
Journal:  J Comput Aided Mol Des       Date:  2019-11-06       Impact factor: 3.686

4.  Proton-Coupled Conformational Allostery Modulates the Inhibitor Selectivity for β-Secretase.

Authors:  Robert C Harris; Cheng-Chieh Tsai; Christopher R Ellis; Jana Shen
Journal:  J Phys Chem Lett       Date:  2017-09-21       Impact factor: 6.475

Review 5.  Sequence, Structural Analysis and Metrics to Define the Unique Dynamic Features of the Flap Regions Among Aspartic Proteases.

Authors:  Lara McGillewie; Muthusamy Ramesh; Mahmoud E Soliman
Journal:  Protein J       Date:  2017-10       Impact factor: 2.371

6.  Structure-Activity Relationship Analysis of Flavonoids and Its Inhibitory Activity Against BACE1 Enzyme Toward a Better Therapy for Alzheimer's Disease.

Authors:  Nur Intan Saidaah Mohamed Yusof; Zafirah Liyana Abdullah; Norodiyah Othman; Fazlin Mohd Fauzi
Journal:  Front Chem       Date:  2022-06-27       Impact factor: 5.545

7.  L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases β-amyloid peptide production in HEK293-APPswe cells.

Authors:  Qin Lu; Wu-Yan Chen; Zhi-Yuan Zhu; Jing Chen; Ye-Chun Xu; Morakot Kaewpet; Vatcharin Rukachaisirikul; Li-Li Chen; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

8.  Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.

Authors:  Fredrik Jeppsson; Susanna Eketjäll; Juliette Janson; Sofia Karlström; Susanne Gustavsson; Lise-Lotte Olsson; Ann-Cathrine Radesäter; Bart Ploeger; Gvido Cebers; Karin Kolmodin; Britt-Marie Swahn; Stefan von Berg; Tjerk Bueters; Johanna Fälting
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

9.  A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors.

Authors:  Yu-Chen Yen; Annalissa M Kammeyer; Jagannadharao Tirlangi; Arun K Ghosh; Andrew D Mesecar
Journal:  ACS Chem Neurosci       Date:  2021-02-05       Impact factor: 5.780

10.  Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders.

Authors:  Payyalot Koyiparambath Vishal; Jong Min Oh; Ahmed Khames; Mohamed A Abdelgawad; Aathira Sujathan Nair; Lekshmi R Nath; Nicola Gambacorta; Fulvio Ciriaco; Orazio Nicolotti; Hoon Kim; Bijo Mathew
Journal:  Pharmaceutics       Date:  2021-06-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.